Talking Biotech with Dr. Kevin Folta Glyphosate 10 Years After IARC - Dr. Robert Tarone
51 snips
Aug 9, 2025 Dr. Robert Tarone, a retired scientist specializing in cancer statistics, joins the discussion to scrutinize the IARC's decade-old classification of glyphosate as a probable carcinogen. He highlights flaws in the evaluation process and emphasizes the lack of credible data linking glyphosate to cancer. The conversation also dives into the legal repercussions for manufacturers, societal perceptions shaped by misinformation, and the necessity for rigorous scientific methodologies in this heated debate.
AI Snips
Chapters
Transcript
Episode notes
Working Group Member Took Legal Role
- Robert Tarone notes Christopher Poirier served as an invited expert on Monograph 112.
- Within two weeks of IARC's conclusion he signed with a law firm to assist litigation against Monsanto.
Exculpatory Data Excluded From Analysis
- Robert Tarone says IARC excluded exculpatory mouse and rat data when assessing glyphosate.
- This selective use of data undermined the animal-evidence basis for the probable-carcinogen conclusion.
Renal Tumor Claims Are Statistically Fragile
- IARC's summary emphasized an increased trend in renal tumors in male mice from one study.
- Robert Tarone shows the statistical methods used were inappropriate and the reported P-values were misleading.